Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Baraclude

Teva Pharma logo

FDA turns down Teva’s Huntington’s disease drug

Has requested further analysis on certain metabolites of the chorea candidate

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

GSK’s morality gene

The firm is mutating in important ways - we should watch carefully

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

Gilead Sciences

Gilead must pay just $200m for hep C patents, says jury

Merck & Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

- PMLiVE

FDA approves new drugs from Teva, Lilly and Elusys

Cinqair, Taltz and Anthim have all been given the green light in the US

- PMLiVE

Opt in or opt out?

Changes to European patent law raise a number of questions for the industry

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links